What the FDA labels say about taking them together
Esomeprazole and nilotinib
Esomeprazole's FDA label of March 19, 2024 names nilotinib in its drug interactions (prescription label) section; nilotinib's label does not name esomeprazole itself but warns about its class (Proton pump inhibitors (PPIs)). The esomeprazole label: “Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity”
Check it at the source: the esomeprazole FDA label on DailyMed (effective March 19, 2024, Haleon US Holdings LLC); the nilotinib FDA label on DailyMed (effective December 16, 2025, Novartis Pharmaceuticals Corporation).
What does the esomeprazole label say about nilotinib?
Esomeprazole label, drug interactions (prescription label)Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole is an enantiomer, in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF …
Source: FDA drug label (Nexium 24HR), NDA204655 (Astrazeneca Lp), as published by Haleon US Holdings LLC, effective March 19, 2024 (SPL set 4513934d-0cf0-40fc-a348-b4e75a33b094), via openFDA; the full label on DailyMed
What does the nilotinib label say about esomeprazole?
Nilotinib's label does not name esomeprazole itself; it warns about its class (Proton pump inhibitors (PPIs)):
Nilotinib label, drug interactionsAvoid concomitant use with Tasigna. Use short-acting antacids or H2 blockers as an alternative to proton pump inhibitors.
Nilotinib label, drug interactionsProton Pump Inhibitors Concomitant use with a proton pump inhibitor (PPI) decreased nilotinib concentrations compared to Tasigna alone [see Clinical Pharmacology (12.3)], which may reduce Tasigna efficacy.
Source: FDA drug label (Tasigna), Novartis Pharmaceuticals Corporation, effective December 16, 2025 (SPL set 6093952a-5248-45cb-ad17-33716a411146), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Esomeprazole | Nilotinib | |
|---|---|---|
| Labeled for | Acid reflux and ulcers | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.145 per capsule 20 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once